LambdaTest and Wipro forge a pioneering partnership, integrating Wipro’s Gen AI-powered QE capabilities with LambdaTest’s HyperExecute, to revolutionize software testing on the Cloud with advanced AI capabilities. San Francisco , Dec. 11, 2023 (GLOBE NEWSWIRE) — LambdaTest, a leading cloud-based unified
Leather Supplier Lowers Emissions: Now and in the Future ROCHESTER HILLS, Mich., Dec. 11, 2023 (GLOBE NEWSWIRE) — Pangea, automotive leather supplier, announces the launch of their second sustainability report, key progress, and a line of advanced products. The company is
Fortinet harnesses more than a decade of AI innovation and deep threat expertise to empower customers with a cutting-edge GenAI tool that upskills cybersecurity teams SUNNYVALE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — Fortinet® (NASDAQ: FTNT), the global cybersecurity leader
Acquisition adds smelting capability to serve spent automotive catalyst customers in Europe, Middle East and Africa Complements ECMS recycling operations and global precious metal services Broadens range of materials that can be processed by ECMS Closing of transaction expected in
Accomplished executives bring decades of insurance and technology expertise to new board roles Barbara Bufkin BOSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) — Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance,
Recognition shows why MSPs consider Acronis a best-of-breed solution for modern cybersecurity Acronis Visionary Approach to Cybersecurity Highlighted in Frost Radar™: Endpoint Security, 2023 BURLINGTON, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) — Acronis, a global leader in cyber protection, has
Recognition shows why MSPs consider Acronis a best-of-breed solution for modern cybersecurity Acronis Visionary Approach to Cybersecurity Highlighted in Frost Radar™: Endpoint Security, 2023 BURLINGTON, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) — Acronis, a global leader in cyber protection, has
Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — AiViva Biopharma Inc., a clinical-stage biotechnology company, announced completion of their first trial administering AIV001 (axitinib) to patients diagnosed with basal cell carcinoma